Surfactant Demand KAER targets preclinical and clinical needs for surfactant aerosol therapy to treat NRDS, ARDS, ALI and other respiratory conditions, presenting a clear access point for hospitals and neonatal care centers seeking advanced aerosol solutions.

Aerosol Innovation KAER’s patented SUPRAER technology enables aerosolizing viscous fluids and high molecular weight agents at clinically relevant doses, offering a differentiator for partners aiming to deploy efficient deep lung delivery in respiratory disease programs.

Partnership Opportunities The company is actively seeking partners to facilitate rapid implementation of its aerosol delivery platform across indications such as IPF, hospital acquired pneumonia, TB, NSCLC and other debilitating lung diseases, expanding potential collaboration channels with pharma and medical device manufacturers.

Clinical Expansion Fit With a focus on critical care respiratory conditions and imminent need areas like ARDS and NRDS, there is potential to align with hospitals, neonatology units, and transplant centers looking to advance surfactant therapies and aerosol delivery in acute and chronic settings.

Commercial Readiness KAER operates with a lean team and ongoing revenue generation, suggesting alignment with contract development, toll manufacturing, and co-development deals where large pharma seek early access to novel aerosol platforms without bearing full R&D burden.